
Mark Stein, PhD, ABPP
Personal Statement
I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to our behavioral group treatment programs and treatment recommendations. The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves diagnostic evaluations and consultations for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for individuals with ADHD. I have assisted in the development of several stimulant and non stimulant medications, and participated in many clinical trials. Currently, we are conducting a study for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication and behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD, and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.Education
Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago
Department Affiliations
Centers/Programs
Other Affiliations
PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic
Center for Child Health, Behavior, and Development
Brotman Baty Institute
Scholarly Expertise
- Adolescent/young adult
- Attention Deficit Disorder (ADD)
- Behavioral genetics
- Child and adolescent psychiatry/psychology
- Collaborative Care / Integrated Care
- Consult psychiatry/psychology
- Developmental neuroscience
- Ethics
- Health services and health policy
- Measurement-based care
- Medically complex
- Outpatient psychiatry/psychology
- Primary care
- Psychiatric specialties
- Randomized controlled trial
- Settings
- Telemedicine
- Telepsychiatry/psychology
Recent Publications
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
(2023 May 3)
Oncologist
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL
(2023 May 3)
Oncologist
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL
Parent Behavior Management Training for Child ADHD Enhanced to Address Health Behaviors: Comparison of Telemedicine "Telegroup" Versus In-Person Delivery.
(2023 Apr 18)
J Atten Disord
Gonzalez ES, Tran N, Wholly D, Kuhn M, Stein MA, Mendoza J, Ola C, Sasser T, Tandon PS
(2023 Apr 18)
J Atten Disord
Gonzalez ES, Tran N, Wholly D, Kuhn M, Stein MA, Mendoza J, Ola C, Sasser T, Tandon PS
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
(2023 Apr 10)
Oncotarget 14(): 302-315
Spencer KR, Portal DE, Aisner J, Stein MN, Malhotra J, Shih W, Chan N, Silk AW, Ganesan S, Goodin S, Gounder M, Lin H, Li J, Cerchio R, Marinaro C, Chen S, Mehnert JM
(2023 Apr 10)
Oncotarget 14(): 302-315
Spencer KR, Portal DE, Aisner J, Stein MN, Malhotra J, Shih W, Chan N, Silk AW, Ganesan S, Goodin S, Gounder M, Lin H, Li J, Cerchio R, Marinaro C, Chen S, Mehnert JM
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
(2023 Mar)
J Immunother Cancer 11(3):
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H
(2023 Mar)
J Immunother Cancer 11(3):
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
(2023 Feb)
J Immunother Cancer 11(2):
Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y
(2023 Feb)
J Immunother Cancer 11(2):
Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y
Show complete publication list »